Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24112532 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL28839694 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL26115001 | 0.94 | CTSS (0.47) | CTSSCTSKCTSLCTSB | |
| SCHEMBL29531620 | 0.93 | CTSS (0.46) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24828157 | 0.91 | CTSL (0.53) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24425249 | 0.89 | — | — | |
| SCHEMBL24582694 | 0.88 | CTSS (0.44) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24113127 | 0.88 | CTSL (0.47) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24189177 | 0.88 | CTSS (0.41) | CTSSCTSK | |
| SCHEMBL29332822 | 0.88 | CTSS (0.41) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-4166539-A1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11541034-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-115043900-A | Peptide-like compound and application thereof in preparation of 2019-nCoV main protease inhibitor | 深圳博瑞医药科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11351149-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2021250648-A1 | NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | PFIZER INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSS 1307/4885CTSK 1493/4885CTSL 635/4885 |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSS 1307/4885CTSK 1493/4885CTSL 635/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSS 7/4885CTSK 43/4885CTSL 3/4885 |
| US-11541034-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSS 1307/4885CTSK 1493/4885CTSL 635/4885 |
| US-11351149-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSS 1307/4885CTSK 1493/4885CTSL 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.